Agenus Inc 10-Q for FY2026 Q3
Agenus Inc (AGEN)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 06, 2026
About this 10-Q
Agenus Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Agenus plans ROBBIN, a global Phase 3 trial of neoadjuvant BOT/BAL in Stage II and Stage III MSS colon cancer. Substantial doubt exists about going concern; existing resources are expected to fund operations through the third quarter of 2027. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $31.49M
- up 4.1% from $30.24M a year earlier
- Net income
- $2.73M
- down 95.7% from net income of $63.91M a year earlier
- Diluted EPS
- $0.02
- down 99.0% from $1.94 a year earlier